Clinical Trial Update: Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether diphenoxylate/atropine reduces FDG activity during F-18 FDG PET imaging in lymphoma patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• LOMOTIL (Diphenoxylate hydrochloride and atropine sulfate)

Snippet

Sponsor: Mayo Clinic | Conditions: Lymphoma | Phase 3 | Status: COMPLETED